in-PharmaTechnologist.com presents its weekly low-down of the latest movers and shakers in the world of pharmaceuticals, including news from Teva, Valeant and AcelRx.
Teva Pharmaceuticals has drafted in Itzhak Krinsky to replace Moshe Manor as chairman of Teva Japan and Teva South Korea.
Manor will also retire from his role as president and CEO of Teva Asia-Pacific, following a 28-year career with the firm.
Krinsky, who also takes on the role of head of business development in Asia-Pacific, will take on his new position next month after serving as executive VP of corporate business development for the firm since 2005.
“As part of our global strategic plan and in response to our growing presence in Asia-Pacific, we are positioning this part of our business to focus on the strong growth prospects in this region,” Jeremy Levin, Teva’s president and CEO said.
Rajiv De Silva has announced that he will quit as president and CEO of speciality pharmaceuticals for Valeant.
Of the matter, the firm said only that he wishes to “pursue other interests”.
De Silva will remain with the company until the end of the year to ensure integration efforts following the recent acquisition of Medicis go smoothly.
Michael Pearson, chairman and CEO said: "Although his leadership will be missed, the company has created and developed a strong management team with Rajiv's assistance that I am confident will lead us successfully through this transition period and into the future."
Steven Derks has been named president and CEO of the Muscular Dystrophy Association (MDA)
He is currently the CEO of the American Cancer Society.
"Steve brings with him a passion for making a difference to patients and families, as well as a broad range of executive leadership skills in nonprofit health care and policy management," said chairman Rodney Howell.
AcelRx has hired Mike Royal as chief of clinical affairs.
He joins from Cadence, where he was VP of clinical development and medical affairs.
Richard King, AcelRx's president and CEO said: "I believe Mike's broad experience and proven track record will be exceptionally helpful to AcelRx as we approach late-stage clinical development and commercialization of our lead product, the Sufentanil NanoTab PCA System."
Circassia has appointed Stewart Sharpe as VP of commercial operations.
Previously he was head of commercial and business development at Astellas .
Steve Harris, CEO said: “We believe our ToleroMune technology (T cell allergy tech) has the potential to revolutionise allergy treatment, and as we move out lead programme into the final phase of development it is the ideal time to ramp up the extensive commercial preparations required for the successful international launch of our first product.”